We established a cohort of 180 patients undergoing surgery for esophageal cancer and analyzed the samples using proteomic techniques to indentify biomarkers and therapeutic targets for esophageal cancer and further explore how these factors modulate the immune microenvironment and mediate the specific mechanism of immunotherapy response or drug resistance.